Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06892028 · ClinicalTrials.gov registry record · NA
EEG-based Personalized Transcranial Magnetic Stimulation (eTMS) to Treat Post-Traumatic Stress Disorder
A NA study of Stress Disorder, Post Traumatic, sponsored by Wave Neuroscience.
- Recruiting
- Registry status
- NA
- Development phase
- 110
- Enrollment target
- 2
- Study locations
NCT06892028: Recruiting NA study of Stress Disorder, Post Traumatic, sponsored by Wave Neuroscience.
NCT06892028 is a NA study of Stress Disorder, Post Traumatic that is actively recruiting participants, run by Wave Neuroscience. The registered enrollment target is 110 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06892028, a NA study of Stress Disorder, Post Traumatic, is actively recruiting participants, sponsored by Wave Neuroscience.
- RECRUITING
- Registry status
- NA
- Development phase
- 110 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a randomized, sham controlled study of the Electroencephalogram (EEG) based Transcranial Magnetic Stimulation (eTMS) treatment for Post-Traumatic Stress Disorder (PTSD). The recruitment goal is 110 participants who are United States Military veterans or first responders (e.g., firefighters, police, paramedics, etc.). The Study includes an EEG recording in order to determine the optimal treatment parameters for the eTMS system, followed by 15 in-office visits that take place over 21-28 total days. Two eTMS treatment sessions are administered during each office visit.
Primary Outcome
The Post Traumatic Stress Disorder (PTSD) Checklist for Diagnostic and Statistical Manual of Mental Disorders, 5th Ed. (DSM-5), commonly referred to as PCL-5, is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD. It is used to monitor symptom change during and after treatment. Each item is scored from 0 to 5 as the participant's estimate of the severity of the symptom (0 = Not at all, 1=A little bit, 2 = Moderately, 3 = Quite a bit, 4 = Extremely). The final score range i
Conditions Studied
Interventions
- DEVICE EEG-based personalized TMS
- DEVICE Sham Comparator
Study Locations (2)
Ohio
- Wright State University - Dayton
- D2 Human Performance Center - Pickerington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2025-02-12 |
| Est. Completion | 2026-01-31 |
| Phase | NA |
What NCT06892028 shows while recruiting
NCT06892028 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Stress Disorder, Post Traumatic appearing as the primary indexed condition, and to 2 interventions - of which EEG-based personalized TMS is the first listed.
NCT06892028 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06892028 about?
NCT06892028 is a clinical study titled "EEG-based Personalized Transcranial Magnetic Stimulation (eTMS) to Treat Post-Traumatic Stress Disorder". This is a randomized, sham controlled study of the Electroencephalogram (EEG) based Transcranial Magnetic Stimulation (eTMS) treatment for Post-Traumatic Stress Disorder (PTSD). The recruitment goal is 110 participants who are United States Military veterans or first responders (e.g., firefighters, ...
What is the current status of trial NCT06892028?
This trial is currently recruiting. It is a NA study. The enrollment target is 110 participants. The study started on 2025-02-12. Estimated completion is 2026-01-31.
What conditions does trial NCT06892028 study?
This clinical trial studies the following conditions: Stress Disorder, Post Traumatic.
What interventions are being tested in trial NCT06892028?
The interventions under investigation include: EEG-based personalized TMS (DEVICE), Sham Comparator (DEVICE).
Who is sponsoring clinical trial NCT06892028?
This trial is sponsored by Wave Neuroscience, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06892028 being conducted?
This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stress Disorder, Post Traumatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06892028's enrollment target sits among peer trials
110 816th of 2000 higher than 1,176 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Acceptability and Feasibility of Work-Oriented Social-Cognitive Skills Training for Veterans With Serious Mental Illness
RECRUITING · NA
-
Prazosin Treatment for Combat Trauma PTSD (Post-Traumatic Stress Disorder) Nightmares and Sleep Disturbance
COMPLETED · Phase 4
-
Integrated Cognitive Behavioral Therapy (ICBT) for Posttraumatic Stress Disorder (PTSD) and Substance Use Disorders
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI